IDH1 and neoplasm: On the other hand, in our cohort eleven patients presented IDH1 mutated tumor tissue and no IDH1 mutation in plasma, suggesting that the blood-brain barrier could limit the release of cfDNA and consequently, the detection of IDH1 mutation.